Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo.

Ghosh S, Sharma G, Travers J, Kumar S, Choi J, Jun HT, Kehry M, Ramaswamy S, Jenkins D.

Mol Cancer Ther. 2019 Mar;18(3):632-641. doi: 10.1158/1535-7163.MCT-18-0836. Epub 2018 Dec 26.

PMID:
30587557
2.

Synthesis and Optical Properties of [Cu6E6(SnPh)2(PPh2Et)6] (E = S, Se, Te) Cluster Molecules.

Eichhöfer A, Kühn M, Lebedkin S, Kehry M, Kappes MM, Weigend F.

Inorg Chem. 2017 Aug 7;56(15):9330-9336. doi: 10.1021/acs.inorgchem.7b01495. Epub 2017 Jul 21.

PMID:
28731683
3.

Mammalian cell display and somatic hypermutation in vitro for human antibody discovery.

King DJ, Bowers PM, Kehry MR, Horlick RA.

Curr Drug Discov Technol. 2014 Mar;11(1):56-64. Review.

PMID:
23978037
4.

Mammalian cell display for the discovery and optimization of antibody therapeutics.

Bowers PM, Horlick RA, Kehry MR, Neben TY, Tomlinson GL, Altobell L, Zhang X, Macomber JL, Krapf IP, Wu BF, McConnell AD, Chau B, Berkebile AD, Hare E, Verdino P, King DJ.

Methods. 2014 Jan 1;65(1):44-56. doi: 10.1016/j.ymeth.2013.06.010. Epub 2013 Jun 20.

PMID:
23792919
5.

EC144 is a potent inhibitor of the heat shock protein 90.

Shi J, Van de Water R, Hong K, Lamer RB, Weichert KW, Sandoval CM, Kasibhatla SR, Boehm MF, Chao J, Lundgren K, Timple N, Lough R, Ibanez G, Boykin C, Burrows FJ, Kehry MR, Yun TJ, Harning EK, Ambrose C, Thompson J, Bixler SA, Dunah A, Snodgrass-Belt P, Arndt J, Enyedy IJ, Li P, Hong VS, McKenzie A, Biamonte MA.

J Med Chem. 2012 Sep 13;55(17):7786-95. doi: 10.1021/jm300810x. Epub 2012 Aug 31.

PMID:
22938030
6.

Transient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults.

Yu S, Ellis JS, Dunn R, Kehry MR, Braley-Mullen H.

Int Immunol. 2012 Apr;24(4):233-42. doi: 10.1093/intimm/dxs003. Epub 2012 Jan 31.

7.

B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis.

Hamel KM, Cao Y, Ashaye S, Wang Y, Dunn R, Kehry MR, Glant TT, Finnegan A.

J Immunol. 2011 Nov 1;187(9):4900-6. doi: 10.4049/jimmunol.1101844. Epub 2011 Sep 23.

8.

Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies.

Serreze DV, Chapman HD, Niens M, Dunn R, Kehry MR, Driver JP, Haller M, Wasserfall C, Atkinson MA.

Diabetes. 2011 Nov;60(11):2914-21. doi: 10.2337/db11-0705. Epub 2011 Sep 16.

9.

An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.

Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR, Shlomchik MJ.

J Immunol. 2011 Oct 1;187(7):3888-94. doi: 10.4049/jimmunol.1101629. Epub 2011 Aug 26.

10.

B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M, Packard TA, Cambier JC, Liu FT, Lindor K, Coppel RL, Ansari AA, Gershwin ME.

Hepatology. 2011 Feb;53(2):527-35. doi: 10.1002/hep.24044. Epub 2010 Dec 28.

11.

EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity.

Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, Luchetti D, Biamonte MA, Shi J, Lundgren K, Manning A, Kehry MR.

J Immunol. 2011 Jan 1;186(1):563-75. doi: 10.4049/jimmunol.1000222. Epub 2010 Dec 3.

12.

Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis.

Kyaw T, Tay C, Khan A, Dumouchel V, Cao A, To K, Kehry M, Dunn R, Agrotis A, Tipping P, Bobik A, Toh BH.

J Immunol. 2010 Oct 1;185(7):4410-9. doi: 10.4049/jimmunol.1000033. Epub 2010 Sep 3.

13.

G alpha q-containing G proteins regulate B cell selection and survival and are required to prevent B cell-dependent autoimmunity.

Misra RS, Shi G, Moreno-Garcia ME, Thankappan A, Tighe M, Mousseau B, Kusser K, Becker-Herman S, Hudkins KL, Dunn R, Kehry MR, Migone TS, Marshak-Rothstein A, Simon M, Randall TD, Alpers CE, Liggitt D, Rawlings DJ, Lund FE.

J Exp Med. 2010 Aug 2;207(8):1775-89. doi: 10.1084/jem.20092735. Epub 2010 Jul 12.

14.

Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH.

Arthritis Rheum. 2010 Aug;62(8):2443-57. doi: 10.1002/art.27515.

15.

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.

Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME.

Hepatology. 2009 Dec;50(6):1893-903. doi: 10.1002/hep.23238. Erratum in: Hepatology. 2010 Jan;51(1):358.

16.

Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, Kehry MR, Laufer TM, Iwasaki A.

J Exp Med. 2008 Dec 22;205(13):3041-52. doi: 10.1084/jem.20082039. Epub 2008 Dec 1.

17.

Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization.

Wu GD, He Y, Chai NN, Toyoda M, Dunn R, Kehry MR, Klein AS, Jordan SC.

Transpl Immunol. 2008 Jul;19(3-4):178-86. doi: 10.1016/j.trim.2008.05.004. Epub 2008 Jun 10.

PMID:
18595710
18.

Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates.

Van Scott MR, Mertsching E, Negrou E, Miles J, Stallings HW 3rd, Graff C, Kehry MR.

Clin Immunol. 2008 Sep;128(3):340-8. doi: 10.1016/j.clim.2008.05.001. Epub 2008 Jun 25.

PMID:
18583194
19.

B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice.

Yu S, Dunn R, Kehry MR, Braley-Mullen H.

J Immunol. 2008 Jun 1;180(11):7706-13.

20.

B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.

Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, Albelda SM.

J Immunother. 2008 Jun;31(5):446-57. doi: 10.1097/CJI.0b013e31816d1d6a.

PMID:
18463540
21.

Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity.

Hamel K, Doodes P, Cao Y, Wang Y, Martinson J, Dunn R, Kehry MR, Farkas B, Finnegan A.

J Immunol. 2008 Apr 1;180(7):4994-5003.

22.

A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.

Mertsching E, Bafetti L, Hess H, Perper S, Giza K, Allen LC, Negrou E, Hathaway K, Hopp J, Chung J, Perret D, Shields M, Saxon A, Kehry MR.

J Allergy Clin Immunol. 2008 Feb;121(2):441-447.e5. Epub 2007 Oct 18.

PMID:
17949802
23.

Depletion of B cells in murine lupus: efficacy and resistance.

Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ.

J Immunol. 2007 Sep 1;179(5):3351-61.

24.

An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalpha.

Demarest SJ, Hopp J, Chung J, Hathaway K, Mertsching E, Cao X, George J, Miatkowski K, LaBarre MJ, Shields M, Kehry MR.

J Biol Chem. 2006 Oct 13;281(41):30755-67. Epub 2006 Aug 11.

25.

Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms.

Azimzadeh AM, Pfeiffer S, Wu G, Schröder C, Zorn GL 3rd, Kelishadi SS, Ozkaynak E, Kehry M, Atkinson JB, Miller GG, Pierson RN 3rd.

Transplantation. 2006 Jan 27;81(2):255-64.

PMID:
16436970
26.

Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates.

Azimzadeh AM, Pfeiffer S, Wu GS, Schröder C, Zhou H, Zorn GL 3rd, Kehry M, Miller GG, Rose ML, Pierson RN 3rd.

Am J Transplant. 2005 Oct;5(10):2349-59.

27.

Signaling and protein associations of a cell permeable CD40 complex in B cells.

Zoog SJ, Papov VV, Pullen SS, Jakes S, Kehry MR.

Mol Immunol. 2004 Jan;40(10):681-94.

PMID:
14644094
28.

The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Ahonen C, Manning E, Erickson LD, O'Connor B, Lind EF, Pullen SS, Kehry MR, Noelle RJ.

Nat Immunol. 2002 May;3(5):451-6. Epub 2002 Apr 22.

29.

Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent.

Manning E, Pullen SS, Souza DJ, Kehry M, Noelle RJ.

Eur J Immunol. 2002 Jan;32(1):39-49.

30.

Molecular characterization of CD40 signaling intermediates.

Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ.

J Biol Chem. 2001 Nov 16;276(46):43334-42. Epub 2001 Sep 18.

31.

Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schönbeck U.

J Clin Invest. 2001 May;107(9):1117-26.

32.

Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.

McWhirter SM, Pullen SS, Werneburg BG, Labadia ME, Ingraham RH, Crute JJ, Kehry MR, Alber T.

Cold Spring Harb Symp Quant Biol. 1999;64:551-62. Review. No abstract available.

PMID:
11232332
34.

CD40 ligation induces tissue factor expression in human vascular smooth muscle cells.

Schönbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P.

Am J Pathol. 2000 Jan;156(1):7-14.

35.

Ligation of CD28 in vivo induces CD40 ligand expression and promotes B cell survival.

Yin D, Zhang L, Wang R, Radvanyi L, Haudenschild C, Fang Q, Kehry MR, Shi Y.

J Immunol. 1999 Oct 15;163(8):4328-34.

37.

High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.

Pullen SS, Labadia ME, Ingraham RH, McWhirter SM, Everdeen DS, Alber T, Crute JJ, Kehry MR.

Biochemistry. 1999 Aug 3;38(31):10168-77.

PMID:
10433725
38.

Crystallographic analysis of CD40 recognition and signaling by human TRAF2.

McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8408-13.

39.

Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.

Hermans IF, Ritchie DS, Daish A, Yang J, Kehry MR, Ronchese F.

J Immunol. 1999 Jul 1;163(1):77-81.

41.

Interaction of B cells with activated T cells reduces the threshold for CD40-mediated B cell activation.

Klaus GG, Holman M, Johnson-Léger C, Christenson JR, Kehry MR.

Int Immunol. 1999 Jan;11(1):71-9.

PMID:
10050675
42.

Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha.

Li J, Peet GW, Pullen SS, Schembri-King J, Warren TC, Marcu KB, Kehry MR, Barton R, Jakes S.

J Biol Chem. 1998 Nov 13;273(46):30736-41.

43.
44.

Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination.

Ballantyne J, Henry DL, Muller JR, Briere F, Snapper CM, Kehry M, Marcu KB.

J Immunol. 1998 Aug 1;161(3):1336-47. Erratum in: J Immunol 1999 Mar 1;162(5):3103.

45.

Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4.

Hasbold J, Lyons AB, Kehry MR, Hodgkin PD.

Eur J Immunol. 1998 Mar;28(3):1040-51.

46.

Regulation of Ku expression in normal murine B cells by stimuli that promote switch recombination.

Zelazowski P, Max EE, Kehry MR, Snapper CM.

J Immunol. 1997 Sep 15;159(6):2559-62.

PMID:
9300672
47.
48.

B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching.

Snapper CM, Rosas FR, Zelazowski P, Moorman MA, Kehry MR, Bravo R, Weih F.

J Exp Med. 1996 Oct 1;184(4):1537-41.

49.

BCL-6 expression during B-cell activation.

Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR, Staudt LM.

Blood. 1996 Jun 15;87(12):5257-68.

50.

IFN-gamma is a potent inducer of Ig secretion by sort-purified murine B cells activated through the mIg, but not the CD40, signaling pathway.

Snapper CM, Rosas F, Moorman MA, Jin L, Shanebeck K, Klinman DM, Kehry MR, Mond JJ, Maliszewski CR.

Int Immunol. 1996 Jun;8(6):877-85.

PMID:
8671677

Supplemental Content

Support Center